{"id":46052,"date":"2024-02-14T07:33:14","date_gmt":"2024-02-14T07:33:14","guid":{"rendered":"https:\/?p=46052"},"modified":"2024-02-14T07:33:14","modified_gmt":"2024-02-14T07:33:14","slug":"how-public-health-crises-impact-edwards-lifesciences-corp","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/how-public-health-crises-impact-edwards-lifesciences-corp\/","title":{"rendered":"How Public Health Crises Impact Edwards Lifesciences Corp"},"content":{"rendered":"

Public health crises possess the potential to disrupt hospital systems substantially, causing postponement or even cancellation of elective procedures. This disruption directly impacts <\/span>Edwards Lifesciences Corp’s (EW: NYE<\/span><\/a>) product usage and in effect, their overall financial standing.\u00a0<\/span><\/p>\n

 <\/p>\n

Stock Target Advisor\u2019s Take on Edwards Lifesciences:<\/strong><\/h2>\n

Stock Target Advisor currently gives Edwards Lifesciences Corp a Buy rating with a target price of $81.67. Even though this suggests a projected price decrease of 5.32% in the next 12 months, the recommendation points to the potential for long term growth. For comparison, the average analyst target price stands at $81.45, also indicating a Buy rating.<\/span><\/p>\n

In light of recent stock performance, Edwards Lifesciences Corp has seen a decrease of 1.99% over the previous week. However, over the past month and the last year, the company\u2019s stock increased by 12.23% and 12.63% respectively.<\/span><\/p>\n

<\/p>\n

\n
\n

EW Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n